The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters. health-related quality-of-Iife (HRQOL) measures. workplace productivity and patient satisfaction. This report presents the HRQOL results.
582 patients (aged 18 to 65 years) with moderate to severe migraine received their customary anti migraine therapy for 12 weeks and then subcutaneous sumatriptan for 24 weeks. The Short Form-36 Health Survey and the MigraineSpecitic Quality of Life Questionnaire were completed at a screening visit (baseline). at the end of the 12-week customary therapy phase. and at 12 and 24 weeks of the sumatriptan phase.
Scores for most of the Short Form-36 dimensions improved significantly (p < 0.(5) after 12 and 24 weeks of sumatriptan therapy compared with 12 weeks of customary therapy. in each country. Similarly. scores on all Migraine-Specific Quality of Life Questionnaire dimensions were signiticantly (p < 0.05: paired t-test) improved after 12 weeks (in all countries) and 24 weeks (in 4 of5 countries) of sumatriptan therapy compared with 12 weeks of customary therapy.
This study demonstrates that. in 5 countries. treatment of migraine attacks with subcutaneous sumatriptan compared with customary therapy was associated with improvements in HRQOL. as measured by both general health status and diseasespecific instruments.